The Company's technology platforms include VIBEX disposable Medi-Jet, disposable multi-use pen injectors and Vision reusable needle-free injectors marketed as TjetA and ZomajetA by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively.
The Parenteral Products Group located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company s reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted VIBEX Medi-Jet and pen injector systems.
KEY WORDS: Nassariids, population biology, Nassarius vibex, sheltered beach, Brazil
Nassarius vibex (Say, 1822) is one of the most important species in the macrofaunal intertidal communities of sheltered sand-muddy beaches on the Silo Paulo and Rio de Janeiro coast (Brazil) (Denadai et al.
vibex between months nested within years and also between levels nested within transects.
The Company's technology platforms include
VIBEX disposable Medi-Jet, disposable multi-use pen injectors and Vision reusable needle-free injectors marketed as Tjet and ZomajetA by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively.
The increases were primarily due to increased investment related to development of our proprietary
VIBEX Medi-Jet auto injector for delivery of methotrexate for the treatment of rheumatoid arthritis, along with an increase in personnel to support our growing pharmaceutical business.
The study assessed the safe usability of VIBEX MTX for self-administration of parenteral MTX in adult RA patients after standardized training by site personnel and review of written instructions.
The performance of the VIBEX Medi-Jet in this clinical study also validates our technology platform upon which we are developing multiple products like MTX and Testosterone, optimizing treatment options and allowing patients to self-administer parenteral medications conveniently at home and potentially reduce overall healthcare costs.
These risks and uncertainties include, among others, changes in revenue growth, difficulties or delays in the initiation, progress, or completion of product development, clinical trials, difficulties or delays in the progress or completion of
VIBEX MTX product development or in the success of the potential
VIBEX MTX NDA.
The purpose of this study was to conduct a cumulative and summative round of simulated usability testing of the VIBEX MTX device in accordance with Food and Drug Administration (FDA) draft guidance "Applying Human Factors and Usability Engineering to Optimize Medical Device Design, dated June 22, 2011".
The results of the study showed that the VIBEX MTX device is safe and effective for intended users, uses and use environments.
